Find, compare & contact
Metenkefalin
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Metenkefalin API 58569-55-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Metenkefalin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Metenkefalin
- Synonyms:
- [met5]-enkephalin , Methionine Enkephalin
- Cas Number:
- 58569-55-4
- DrugBank number:
- DB12668
- Unique Ingredient Identifier:
- 9JEZ9OD3AS
General Description:
Metenkefalin, identified by CAS number 58569-55-4, is a notable compound with significant therapeutic applications. Metenkefalin is an endogenous opioid and beta-endorphin. It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. Metenkefalin, along with , are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.
Indications:
This drug is primarily indicated for: Metenkefalin is indicated in Bosnia for the treatment of relapsing-remitting multiple sclerosis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Metenkefalin are crucial for its therapeutic efficacy: Metenkefalin reaches a Cmax of 1266.14pg/mL, with a Tmax of 0.16h, and an AUC of 360.64pg\*h/mL. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Metenkefalin is an important consideration for its dosing schedule: The half life of metenkefalin is 4.2-39 minutes. This determines the duration of action and helps in formulating effective dosing regimens.
Mechanism of Action:
Metenkefalin functions by: Metenkefalin is an agonist of µ and δ opioid receptors. It also causes immunostimulation at low doses and immunosuppression at higher doses. Metenkefalin can also inhibit the production of aldosterone, deoxycorticosterone, and corticosterone. Unfortunately, the mechanisms by which these effects occur have not been well described in the literature. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Metenkefalin belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds, classified under the direct parent group Oligopeptides. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Amino acids, peptides, and analogues subclass.
Categories:
Metenkefalin is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Enkephalin, Methionine, Enkephalins, Experimental Unapproved Treatments for COVID-19, mu-Opioid Receptor Agonist, Nerve Tissue Proteins, Neuropeptides, Neurotransmitter Agents, Opioid Peptides, Peptides, Proteins, Receptors, Opioid, delta, agonists. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Metenkefalin is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
